In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. - Wikidata - awgldk - TriplyDB

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

http://www.wikidata.org/entity/Q37340504

about

The role of combination medical therapy in the treatment of acromegaly.

P2860

Q38927318-3A8EA764-F899-48DB-923E-81CD8273E047

P2860

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

http://www.wikidata.org/entity/Q37340504

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@en

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@nl

type

label

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@en

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@nl

prefLabel

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@en

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@nl

P1433

Q37340504-CB5FB1F4-37CB-4947-9831-70EFCF7ECE1A

P1476

Q37340504-6C980114-BC06-454C-A0F8-577C8C20B99B

P2093

Q37340504-008D0932-404B-4E12-85F1-F79F92DF5122

Q37340504-322B50C5-6F57-4DEE-8506-4AE4AE08B6E9

Q37340504-3E731629-2D0B-40BC-8148-BC7C882BDD77

Q37340504-876E9F01-B64B-4539-AAC4-2F3F74A3F3DF

Q37340504-967A96F2-C19C-4ADE-BA3C-B1F1BA990A23

Q37340504-A31CE5C0-61BF-4B83-8919-88FBDD1F71A8

Q37340504-CD697783-82CB-4640-AD23-7D15EFBDE2E8

Q37340504-DFE94752-5690-4911-9F70-370D50CF7D0C

Q37340504-E5B5E1DD-7339-4220-BF15-23F01D96AE70

Q37340504-EA539604-EAF6-412C-B92B-BF88EDA0171B

P2860

Q37340504-1D8E2C57-9E51-4D1F-AA9A-2D7845DAC011

Q37340504-2046F751-03E0-4A58-8E62-F392D5F96AA0

Q37340504-2B592179-F136-4D5C-9C4B-9ABFF6089282

Q37340504-3004DFF3-11E7-46FB-B8FC-3D517B53C79E

Q37340504-31696F23-DCC4-4A9F-8193-1D7BDA07A8AB

Q37340504-337CAA4C-FE6B-434B-A075-D3C304342D89

Q37340504-41D38B0A-707C-4FF7-BBE4-6301CF2B61E5

Q37340504-43528987-DA7D-4CCC-A5A2-E2DC66CF78CC

Q37340504-4A6E2FEF-4CE7-42A9-BC0E-6E9BD8F2D820

Q37340504-4C14287E-4F8F-4F0C-A77E-6AC395F91D91

P304

Q37340504-4924E078-02B5-47C0-BC03-A0A55ABFC33B

P31

Q37340504-D24FA926-7233-4E08-8EAE-8348842D9AD4

P356

Q37340504-0037D837-C3D7-4FFC-A0FA-909732204359

P433

Q37340504-28BD1E92-4518-42F0-9835-6FF15C4212F0

P478

Q37340504-1ED9C5AB-93F1-4AA9-B6FE-0B89F4514F41

P50

Q37340504-17A2C8A0-E385-4119-BF55-3E2886AD97FF

Q37340504-3BCC1477-C67F-482A-A596-E542F703A760

Q37340504-4EBF3CCD-515D-439F-9293-5DF092652771

Q37340504-579B3AF2-92F9-4189-B6B1-4AE70E3C52AD

P577

Q37340504-D3C9CE41-3FC1-4758-8AF4-DBE9FA783F2C

P698

Q37340504-C5069FAF-41DA-4226-BF0B-E5B88DB58AC4

P921

Q37340504-28005749-3393-4C61-A34A-11ABE21F419E

P932

Q37340504-67B94025-F869-4CDA-B80A-88D401C0CED0

P356

P1433

Endocrine-related cancer

P1476

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

@en

P2093

Alain Enjalbert

http://www.w3.org/2001/XMLSchema#string

Anne Barlier

http://www.w3.org/2001/XMLSchema#string

Caroline Zeiller

http://www.w3.org/2001/XMLSchema#string

Catherine Roche

http://www.w3.org/2001/XMLSchema#string

Céline Défilles

http://www.w3.org/2001/XMLSchema#string

Marie-Pierre Blanchard

http://www.w3.org/2001/XMLSchema#string

Marily Theodoropoulou

http://www.w3.org/2001/XMLSchema#string

Martin Bidlingmaier

http://www.w3.org/2001/XMLSchema#string

Morgane Pertuit

http://www.w3.org/2001/XMLSchema#string

Thierry Brue

http://www.w3.org/2001/XMLSchema#string

P2860

Intracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GH.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

The role of Stat3 in apoptosis and mammary gland involution. Conditional deletion of Stat3.

A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.

Expert consensus document: A consensus on the medical treatment of acromegaly.

Pegvisomant Treatment in Acromegaly.

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.

Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis.

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.

P304

509-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-16-0140

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Figarella-Branger

Martin Bidlingmaier

Marily Theodoropoulou

Thomas Graillon

P577

2016-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27267119

http://www.w3.org/2001/XMLSchema#string

P921

growth hormone secreting pituitary adenoma

P932

5064756

http://www.w3.org/2001/XMLSchema#string